Get the SPI Wire

LANTERN PHARMA INC.

NASDAQ:LTRN
Annual Meeting

of Shareholders

MEETING DATE

12/01/2026
DEF 14A FILED
10/19/2026
PUBLISHED
10/19/2026 8:15 pm
TIME TO PUBLISH
10/21/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:LTRN · CUSIP 51654W101 · CLASS common stock · CIK 0001763950

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

5
FOR
2
AGAINST
0
WITHHOLD
7
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
To elect six (6) directors to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified.
board
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The Board nominated six current directors, and no nominee is expected to be unable to serve.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To adopt an amendment to the Company’s Certificate of Incorporation to increase the Company’s authorized common stock to 50 million shares.
other
Elevated
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

The filing states future issuances may dilute earnings per share and existing stockholders’ equity and voting rights.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended, to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 250,000 shares.
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states only 175,633 shares remained available for future grants as of the proxy date.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To approve the issuance of up to 3,669,725 shares of the Company’s common stock issuable upon exercise of purchase warrants sold by us to an institutional investor.
other
Elevated
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

The filing states full exercise would issue 3,669,725 additional shares and dilute existing stockholders’ ownership interest.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
auditor
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The Audit Committee appointed EisnerAmper LLP and pre-approved all services provided during 2025 and 2024.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
To approve, on an advisory basis, the compensation of our named executive officers.
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states compensation actually paid decreased from 2024 to 2025 for the CEO and non-CEO NEOs.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
7
To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the named executive officers.
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The Board recommends every one year and states annual votes allow timely, direct input on executive compensation.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

6f57f24ba7f97a64be5cba67fc4680010be22c733a4b1b0745964e0da88dc8b9

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates